Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus everolimus first-line treatment for advanced non-clear cell renal cell carcinoma
ChiCTR2100046574Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and everolimus in non-clear cell renal cell carcinoma (nccRCC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Overall response rate. Started Jun 2021; status: recruiting.
02
Drugs
anlotinibeverolimus
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on ChiCTR2100046574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046574.